Carregando empresa
Just reported
Q3 2026 results
From Gilead Sciences's results release of 29 de outubro de 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 8,3B
+6,8% y/y
+6,4% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ 1,94
-20% y/y
Guided
—
No guide given
Operating income, GAAP
Actual
US$ 3,46B
+4,1% y/y
Guided
—
No guide given
Company outlook
Full year 2026
- EPS, GAAPUS$ 9,88+46% y/y Raised +8,8%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Gilead Sciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And CompanyUS$ 1,35TA+
JNJJohnson & JohnsonUS$ 682,6BA+
MRKMerck & Co., Inc.US$ 362,2BA
NVSNovartis AGUS$ 305,8BA
AMGNAmgen Inc.US$ 252,6BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
BIIBBiogen Inc.28 de out. de 2026BAGraded B, now A
Como ganha dinheiro
- HIV medicines73%
- Liver disease medicines11%
- Cancer medicines11%
- Veklury1%
- Royalties, contracts, and other revenue1%
As participações na receita são estimativas para six months ended June 30, 2026, não números de um relatório oficial.
Concorre com
O que vende6
Biktarvy
A daily tablet used to treat HIV infection in certain patients.
Yeztugo
A tablet and long-acting injection used before exposure to help prevent HIV infection in at-risk adults and adolescents.
Descovy
A tablet used with other medicines to treat HIV, and also used before exposure to help prevent HIV infection in certain at-risk people.
Mostrar mais 3
Trodelvy
An intravenous medicine for certain adults with advanced breast cancer. The latest quarterly report describes its use as a first-line treatment for metastatic triple-negative breast cancer, as well as treatment for some patients with hormone-receptor-positive breast cancer.
Yescarta
A treatment made from a patient's immune cells that are changed to recognize and attack certain blood cancers.
Livdelzi
An oral medicine for primary biliary cholangitis, a chronic disease that damages small bile ducts in the liver.
Quem compra4
- In the United States, large drug wholesalers buy most products for distribution to pharmacies and healthcare providers; Gilead names Cardinal Health, Cencora, and McKesson as major wholesalers.
- Outside the United States, products are sold through Gilead's commercial teams, third-party distributors, and corporate partners.
- Hospitals, clinics, and other healthcare providers prescribe or administer Gilead medicines to patients.
- Government health programs and private insurers pay for or reimburse many prescriptions and related treatments.
Em que se apoia e o que pode quebrá-lo
Do que o negócio depende
- 1Gilead relies on wholesalers to distribute most of its products in the United States and on distributors or corporate partners in some other markets.
- 2It relies on outside manufacturers and testing laboratories for much of the production and testing of its medicines, though it uses multiple suppliers for many products.
- 3Its business depends on regulatory approval and continuing compliance with rules governing drug testing, manufacture, safety, promotion, and sale.
- 4Sales depend on health insurers and government payers covering medicines and on the prices and discounts they accept.
O que pode dar errado
- 1HIV medicines accounted for 72.6% of revenue (six months ended June 30, 2026, high), so changes in demand, competition, coverage, or pricing for those medicines could materially affect sales.
- 2Clinical trials can fail or be delayed, and regulators can limit or reject a medicine's use. In June 2026, Gilead stopped a Trodelvy study in non-small cell lung cancer and recorded a $1.75 billion impairment charge for the related research asset (three months ended June 30, 2026, high).
- 3Generic medicines, competing treatments, patent challenges, and required discounts or rebates can reduce sales or the amount Gilead receives for its medicines.
Demonstrações financeiras completas →
Sobre a Gilead Sciences, Inc.
Gilead discovers, develops, and sells prescription medicines. Its medicines prevent or treat human immunodeficiency virus (HIV), viral hepatitis, cancer, coronavirus disease 2019 (COVID-19), and other serious illnesses. It sells medicines directly through its commercial teams and through wholesalers, distributors, and business partners.
- Sede
- Foster City, California
- Fundada em
- 1987
- Funcionários
- Approximately 17,000 (December 31, 2025, high)
- Listada em
- Nasdaq
- Fim do exercício
- December 31
Construído a partir dos próprios documentos de Gilead Sciences, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.